Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
INCPF
InnoCare Pharma
$1.60
$1.64
$1.60
▼
$1.85
N/AN/A550 shsN/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$68.47
+1.1%
$62.31
$37.31
▼
$70.37
$39.26B0.373.49 million shs3.53 million shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$23.85
-4.8%
$27.99
$13.50
▼
$44.60
$1.62B-0.88490,681 shs579,894 shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
INCPF
InnoCare Pharma
0.00%0.00%0.00%+3.23%-24.88%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
0.00%-1.21%+7.41%+11.68%+77.16%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
0.00%-14.85%-15.52%-26.14%-35.80%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
INCPF
InnoCare Pharma
$1.60
$1.64
$1.60
▼
$1.85
N/AN/A550 shsN/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$68.47
+1.1%
$62.31
$37.31
▼
$70.37
$39.26B0.373.49 million shs3.53 million shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$23.85
-4.8%
$27.99
$13.50
▼
$44.60
$1.62B-0.88490,681 shs579,894 shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
INCPF
InnoCare Pharma
0.00%0.00%0.00%+3.23%-24.88%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
0.00%-1.21%+7.41%+11.68%+77.16%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
0.00%-14.85%-15.52%-26.14%-35.80%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
INCPF
InnoCare Pharma
3.00
BuyN/AN/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
3.11
Buy$65.00-5.07% Downside
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
2.56
Moderate Buy$46.7195.87% Upside

Current Analyst Ratings Breakdown

Latest INCPF, RPRX, and ZBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
UpgradeSell (E+) ➝ Sell (D-)
11/18/2026
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
Boost Price TargetBuy$68.00 ➝ $80.00
11/11/2026
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
UpgradeHold ➝ Strong-Buy
11/5/2026
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
Boost Price TargetBuy$70.00 ➝ $78.00
11/4/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
DowngradeSell (D-) ➝ Sell (E+)
10/28/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Reiterated RatingBuy
10/23/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
UpgradeSell (E+) ➝ Sell (D-)
10/20/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Initiated CoverageEqual Weight$32.00
10/13/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Reiterated RatingBuy$44.00
10/7/2026
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
Boost Price TargetOverweight$65.00 ➝ $67.00
10/6/2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Reiterated RatingSell (E+)
(Data available from 11/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
INCPF
InnoCare Pharma
N/AN/AN/AN/AN/AN/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$2.38B16.52$4.78 per share14.33$17.08 per share4.01
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$10M161.75N/AN/A$3.13 per share7.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
INCPF
InnoCare Pharma
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$770.95M$1.2057.0611.931.3525.68%30.04%14.97%2/10/2027 (Estimated)
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$377.74M-$9.42N/AN/AN/AN/A-144.65%-59.83%N/A

Latest INCPF, RPRX, and ZBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$1.24-$1.65-$0.41-$1.65$10.00 million$10.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
INCPF
InnoCare Pharma
N/AN/AN/AN/AN/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$0.941.37%+24.01%78.33%5 Years
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/AN/AN/AN/AN/A

Latest INCPF, RPRX, and ZBIO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/16/2026
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
quarterly$0.23501.36%11/13/202611/13/202612/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
INCPF
InnoCare Pharma
N/AN/AN/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
0.77
1.29
1.29
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
1.88
9.42
9.42

Institutional Ownership

CompanyInstitutional Ownership
INCPF
InnoCare Pharma
N/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
54.35%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A

Insider Ownership

CompanyInsider Ownership
INCPF
InnoCare Pharma
N/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
18.84%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
22.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
INCPF
InnoCare Pharma
1,259N/AN/ANot Optionable
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
100573.60 million465.54 millionOptionable
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
16767.82 million52.90 millionOptionable

Recent News About These Companies

FY2026 EPS Forecast for Zenas BioPharma Decreased by Analyst
Zenas BioPharma Highlights New Phase 3 Obexelimab Data

New MarketBeat Followers Over Time

Media Sentiment Over Time

InnoCare Pharma OTCMKTS:INCPF

$1.60 0.00 (0.00%)
As of 11/20/2026

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189 and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. The company has a clinical development collaboration with ArriVent Biopharma, Inc. to evaluate the anti-tumor activity and safety of ICP-189 combined with furmonertinib in patients with advanced non-small cell lung cancer. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.

Royalty Pharma stock logo

Royalty Pharma NASDAQ:RPRX

$68.47 +0.75 (+1.11%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$68.52 +0.04 (+0.06%)
As of 11/20/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Zenas BioPharma stock logo

Zenas BioPharma NASDAQ:ZBIO

$23.85 -1.19 (-4.75%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$23.85 0.00 (0.00%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.